Kanghong Pharmaceutical: Independently developed KHN707 tablets received approval for clinical trials.

Kanghong Pharmaceutical announced that the company has received a "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. Its independently developed KHN707 tablets have been approved for clinical trials for insomnia. The drug is a Class 1 chemical drug, belonging to selective orexin receptor antagonists. Previous studies have shown that it has good safety and therapeutic effects in insomnia models. However, there is uncertainty in the drug development, testing, evaluation, and approval process, as well as the results and timeline. Investors are reminded to pay attention to the risks.